AVROBIO Overview
- Year Founded
-
2015

- Status
-
Acquired/Merged
- Employees
-
13

- Latest Deal Type
-
M&A
AVROBIO General Information
Description
Developer of lentiviral-based gene therapies designed to halt or reverse Lysosomal disorders with a single dose. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen and for the treatment of Pompe disease.
Contact Information
Website
www.avrobio.comCorporate Office
- 100 Technology Square
- 6th Floor
- Cambridge, MA 02139
- United States
Corporate Office
- 100 Technology Square
- 6th Floor
- Cambridge, MA 02139
- United States
AVROBIO Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Merger/Acquisition | 20-Jun-2024 | Completed | Generating Revenue | |||
9. Merger/Acquisition | 08-Feb-2023 | Cancelled | Generating Revenue | |||
8. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
7. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
6. Secondary Transaction - Open Market | 28-Sep-2018 | Completed | Clinical Trials - Phase 2 | |||
5. IPO | 21-Jun-2018 | Completed | Clinical Trials - Phase 2 | |||
4. Early Stage VC (Series B) | 02-Feb-2018 | Completed | Clinical Trials - Phase 2 | |||
3. Early Stage VC (Series A) | 30-Mar-2017 | Completed | Clinical Trials - Phase 2 | |||
2. Accelerator/Incubator | 01-Jun-2016 | $1.5M | Completed | Startup | ||
1. Seed Round | 18-Feb-2016 | $1.5M | $1.5M | Completed | Startup |
AVROBIO Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | ||||||||
Series A | ||||||||
Seed | 3,333,333 | $0.000100 | $0.02 | $0.45 | $0.45 | 1x | $0.45 | 4.19% |
AVROBIO Comparisons
Industry
Financing
Details
AVROBIO Competitors (65)
One of AVROBIO’s 65 competitors is Voyager Therapeutics, a Corporation company based in Lexington, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Voyager Therapeutics | Corporation | Lexington, MA | ||||
Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
Alaunos Therapeutics | Formerly VC-backed | Houston, TX | ||||
TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
Biosceptre | Venture Capital-Backed | Cambridge, United Kingdom |
AVROBIO Signals
AVROBIO Former Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
5Y Capital | Venture Capital | Minority | ||
Aisling Capital | Venture Capital | Minority | ||
Atlas Venture | Venture Capital | Minority | ||
Brace Pharma Capital | Corporate Venture Capital | Minority | ||
Citadel Enterprise Americas | Hedge Fund | Minority |
AVROBIO Acquisitions (1)
AVROBIO’s most recent deal was a Reverse Merger with Tectonic Therapeutic for . The deal was made on 30-Jan-2024.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Tectonic Therapeutic | 30-Jan-2024 | Reverse Merger | Drug Discovery |
AVROBIO ESG
Risk Overview
Risk Rating
Updated December, 06, 2022
27 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,480
Rank
Percentile

Pharmaceuticals
Industry
of 905
Rank
Percentile

Biotechnology
Subindustry
of 404
Rank
Percentile

AVROBIO FAQs
-
When was AVROBIO founded?
AVROBIO was founded in 2015.
-
Where is AVROBIO headquartered?
AVROBIO is headquartered in Cambridge, MA.
-
What is the size of AVROBIO?
AVROBIO has 13 total employees.
-
What industry is AVROBIO in?
AVROBIO’s primary industry is Biotechnology.
-
Is AVROBIO a private or public company?
AVROBIO is a Private company.
-
What is AVROBIO’s current revenue?
The current revenue for AVROBIO is
. -
How much funding has AVROBIO raised over time?
AVROBIO has raised $187M.
-
Who are AVROBIO’s investors?
5Y Capital, Aisling Capital, Atlas Venture, Brace Pharma Capital, and Citadel Enterprise Americas are 5 of 9 investors who have invested in AVROBIO.
-
Who are AVROBIO’s competitors?
Voyager Therapeutics, Orchard Therapeutics, Alaunos Therapeutics, TScan Therapeutics, and Biosceptre are some of the 65 competitors of AVROBIO.
-
When was AVROBIO acquired?
AVROBIO was acquired on 20-Jun-2024.
-
Who acquired AVROBIO?
AVROBIO was acquired by Tectonic Therapeutic.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »